GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment

Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug approvals this year.